Sirius Therapeutics Announces Nearly $50 Million Financing to Accelerate Clinical Development of siRNA Therapeutics for Cardiometabolic Diseases
SAN DIEGO & SHANGHAI–(BUSINESS WIRE)–Sirius Therapeutics today announced that it has successfully completed nearly $50 million Series B2 financing to advance clinical development of the Company’s novel siRNA therapeutics for cardiometabolic disorders and continued innovation…